CANCER:

Cervical Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

›

HER-2 mutation	Cervical Cancer	HER-2 mutation	Cervical Cancer	neratinib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) neratinib Sensitive : C2 ESMO 2022 - 3wk	neratinib Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks neratinib Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
PD-L1 negative	Cervical Cancer	PD-L1 negative	Cervical Cancer	pembrolizumab + tirvalimogene teraplasmid Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) pembrolizumab + tirvalimogene teraplasmid Sensitive : C3 ESMO 2022 - 3wk	pembrolizumab + tirvalimogene teraplasmid Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks pembrolizumab + tirvalimogene teraplasmid Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	tisotumab vedotin-tftv Sensitive: A1 - Approval tisotumab vedotin-tftv Sensitive : A1	tisotumab vedotin-tftv Sensitive: A1 - Approval tisotumab vedotin-tftv Sensitive : A1
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	pembrolizumab + bevacizumab Sensitive: A1 - Approval pembrolizumab + bevacizumab Sensitive : A1	pembrolizumab + bevacizumab Sensitive: A1 - Approval pembrolizumab + bevacizumab Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval Krabeva (bevacizumab biosimilar) Sensitive : A1	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval Krabeva (bevacizumab biosimilar) Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	cadonilimab Sensitive: A1 - Approval cadonilimab Sensitive : A1	cadonilimab Sensitive: A1 - Approval cadonilimab Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	CT-P16 (bevacizumab biosimilar) Sensitive: A1 - Approval CT-P16 (bevacizumab biosimilar) Sensitive : A1	CT-P16 (bevacizumab biosimilar) Sensitive: A1 - Approval CT-P16 (bevacizumab biosimilar) Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	paclitaxel + topotecan Sensitive: A2 - Guideline paclitaxel + topotecan Sensitive : A2	paclitaxel + topotecan Sensitive: A2 - Guideline paclitaxel + topotecan Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	mitomycin Sensitive: A2 - Guideline mitomycin Sensitive : A2	mitomycin Sensitive: A2 - Guideline mitomycin Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2
NTRK3 fusion	Cervical Cancer	NTRK3 fusion	Cervical Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Cervical Cancer	NTRK2 fusion	Cervical Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Cervical Cancer	NTRK1 fusion	Cervical Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Cervical Cancer	NTRK3 fusion	Cervical Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Cervical Cancer	NTRK2 fusion	Cervical Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Cervical Cancer	NTRK1 fusion	Cervical Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
TMB-H	Cervical Cancer	TMB-H	Cervical Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2

Cervical Cancer

Associations(104)

Associations
(104)